Paloma Partners’s Roivant Sciences ROIV Stock Holding History

Paloma Partners’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-27,040	Closed	-$312K	–	934
2024 Q3	$312K	Sell	27,040 -770	-3%	-$8.77K	0.01%	790
2024 Q2	$294K	Buy	+27,810	New	+$305K	0.01%	913
2022 Q2	–	Sell	-4,281	Closed	-$21K	–	1656
2022 Q1	$21K	Sell	4,281 -4,530	-51%	-$29.9K	﹤0.01%	1692
2021 Q4	$89K	Buy	+8,811	New	+$73.3K	﹤0.01%	1783

Other funds holding ROIV

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Paloma Partners's ROIV Position: Q4 2024 in Review

Paloma Partners sold out of Roivant Sciences (ROIV) in Q4 2024, closing a stake of 27,040 shares — an estimated $312K sold.

Paloma Partners first reported a position in ROIV in Q4 2021 and held it in 4 quarters. The position peaked at $312K in Q3 2024. 318 funds tracked by Wall St. Rank hold ROIV as of Q4 2024.

Paloma Partners reported no remaining Roivant Sciences position as of Q4 2024 after selling out during the quarter.
Paloma Partners sold 27,040 Roivant Sciences shares in Q4 2024, an estimated $312K.
Paloma Partners first reported a position in Roivant Sciences in Q4 2021 and held it in 4 quarters.
Paloma Partners's Roivant Sciences position peaked at $312K in Q3 2024.
318 funds tracked by Wall St. Rank held Roivant Sciences as of Q4 2024.

Based on Paloma Partners's 13F filing for Q4 2024, filed 14 Feb 2025.